6-氟-7-甲基靛红 | 57817-03-5

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟靛红系列
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 6-氟-7-甲基靛红
• 英文名称: 6-fluoro-7-methylindoline-2,3-dione
• 英文别名: 6-fluoro-7-methylisatin；6-fluoro-7-methyl-1H-indole-2,3-dione
• CAS: 57817-03-5
• 化学式: C₉H₆FNO₂
• mdl: MFCD06409073
• 分子量: 179.151
• InChiKey: SCTZCVLCXNUKGW-UHFFFAOYSA-N

物化性质

• 熔点：
  204-206 °C
• 密度：
  1.399±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  6-氟-7-甲基靛红 在 三氯异氰尿酸 、 硫酸 作用下， 反应 0.5h， 生成 5-chloro-6-fluoro-7-methylindoline-2,3-dione
  参考文献：
  名称：

  [EN] GLYCINE B ANTAGONISTS
  [FR] ANTAGONISTES DE LA GLYCINE B

  摘要：

  该发明涉及公式（I）的2（1H）-喹啉酮衍生物及其药用可接受的盐。该发明还涉及一种制备此类化合物的方法。该发明的化合物是甘氨酸B拮抗剂，因此对于控制和预防各种疾病，包括神经系统疾病，具有用途。

  公开号：

  WO2012164085A1
• 作为产物：
  描述：

  (E)-N-(3-fluoro-2-methylphenyl)-2-(hydroxyimino)acetamide 在 硫酸 作用下， 反应 4.0h， 以63.3%的产率得到6-氟-7-甲基靛红
  参考文献：
  名称：

  一种氮杂环二酮化合物及其制备方法

  摘要：

  本发明提供了一种氮杂环二酮化合物，其特征在于，为如下结构所示的化合物：该化合物对帽依赖性核酸内切酶抑有制活性。

  公开号：

  CN111606928A

文献信息

• Substituted 1,3,4,9-tetrahydropyrano(3,4-B)indole-1-acetic acids
  申请人：American Home Products Corporation

  公开号：US04670462A1

  公开（公告）日：1987-06-02

  Indole derivatives characterized by having a 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid nucleus bearing a substituent in position 1 and 4. The nucleus may be optionally substituted at positions 5, 6, 7 and 8. The derivatives are useful anti-inflammatory and analgesic agents and methods for their preparation and use are also disclosed.

  具有1,3,4,9-四氢吡喃并[3,4-b]吲哚-1-乙酸核的吲哚衍生物，其在位置1和4带有取代基。该核在位置5、6、7和8处可选择性地被取代。这些衍生物是有用的抗炎和镇痛剂，并且还公开了它们的制备和使用方法。
• Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids
  作者：Gordon W. Rewcastle、Graham J. Atwell、Li Zhuang、Bruce C. Baguley、William A. Denny

  DOI：10.1021/jm00105a034

  日期：1991.1

  Analogues of 9-oxo-9H-xanthene-4-acetic acid (XAA) bearing small, lipophilic 5-substituents are among the most dose-potent compounds yet reported with the capability of causing hemorrhagic necrosis of implanted colon 38 tumors in mice. To further extend structure-activity relationships among this class of compound, a series of XAA derivatives bearing two small lipophilic groups at various positions

  带有小的，亲脂性的5个取代基的9-氧代9H-氧杂蒽-4-乙酸（XAA）的类似物是迄今已报道的最强剂量化合物，具有引起小鼠植入的结肠38肿瘤出血性坏死的能力。为了进一步扩展这类化合物之间的构效关系，已经制备并评估了一系列在不同位置带有两个小的亲脂基团的XAA衍生物。特别是5，6-二取代的化合物始终显示出高水平的剂量效力和活性，这表明这是取代的9-氧代-9H-氧杂蒽-4-乙酸中的最佳构型。5,6-二甲基和5-甲基-6-甲氧基是最有效的类似物，
• Use of isatin derivatives as ion channel activating agents
  申请人：——

  公开号：US20020016354A1

  公开（公告）日：2002-02-07

  The present invention relates to ion channel activating agents. More particularly, the present invention relates to a particular class of chemical compounds that has proven useful as openers of SK Ca and IK Ca channels. In further aspects, the present invention relates to the use of these SK/IK channel activating agents for the manufacture of medicaments and pharmaceutical compositions comprising the SK/IK channel activating agents. The SK/IK channel activating agents of the invention are useful for the treatment or alleviation of diseases and conditions associated with the SK/IK channels, in particular respiratory diseases such as asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhea, ischaemia, cerebral ischaemia, ischaemic heart disease, angina pectoris, coronary heart disease, traumatic brain injury, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.

  本发明涉及离子通道激活剂。更具体地说，本发明涉及一类特定的化合物，已被证明对SKCa和IKCa通道的开放具有用处。在进一步方面，本发明涉及利用这些SK/IK通道激活剂制造药物和包含SK/IK通道激活剂的药物组合物。本发明的SK/IK通道激活剂对于治疗或缓解与SK/IK通道相关的疾病和症状非常有用，特别是呼吸道疾病，如哮喘、囊性纤维化、慢性阻塞性肺疾病和鼻涕，痉挛、血管痉挛、冠状动脉痉挛、肾脏疾病、多囊肾病、膀胱痉挛、尿失禁、膀胱排空阻塞、肠易激综合征、胃肠功能障碍、分泌性腹泻、缺血、脑缺血、缺血性心脏病、心绞痛、冠心病、创伤性脑损伤、精神病、焦虑、抑郁、痴呆、记忆和注意力缺陷、阿尔茨海默病、痛经、嗜睡症、雷诺氏病、间歇性跛行、斯约格伦综合征、偏头痛、心律失常、高血压、缺席性癫痫发作、肌肉肌无力、干燥综合征、2型糖尿病、胰岛素过多症、早产、秃头、癌症和免疫抑制。
• [EN] USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS<br/>[FR] UTILISATION DE DERIVES D'ISATINE EN TANT QU'AGENTS D'ACTIVATION DE CANAUX IONIQUES
  申请人：NEUROSEARCH AS

  公开号：WO2000033834A1

  公开（公告）日：2000-06-15

  The present invention relates to ion channel activating agents. More particularly, the present invention relates to a particular class of chemical compounds that has proven useful as openers of SKCa and IKCa channels. In further aspects, the present invention relates to the use of these SK/IK channel activating agents for the manufacture of medicaments, and pharmaceutical compositions comprising the SK/IK channel activating agents. The SK/IK channel activating agents of the invention are useful for the treatment or alleviation of diseases and conditions associated with the SK/IK channels, in particular respiratory diseases such as asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic hearth disease, angina pectoris, coronary hearth disease, traumatic brain injury, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labour, baldness, cancer, and immune suppression.

  本发明涉及离子通道激活剂。更具体地，本发明涉及一类已被证明对SKCa和IKCa通道具有开放作用的化学化合物。在进一步方面，本发明涉及使用这些SK/IK通道激活剂制造药物，以及包括SK/IK通道激活剂的药物组合物。本发明的SK/IK通道激活剂对于治疗或缓解与SK/IK通道相关的疾病和症状非常有用，特别是呼吸系统疾病，如哮喘、囊性纤维化、慢性阻塞性肺疾病和流涕、惊厥、血管痉挛、冠状动脉痉挛、肾功能障碍、多囊肾病、膀胱痉挛、尿失禁、膀胱出口梗阻、肠易激综合征、胃肠功能障碍、分泌性腹泻、缺血、脑缺血、缺血性心脏病、心绞痛、冠心病、创伤性脑损伤、精神病、焦虑、抑郁症、痴呆、记忆和注意力缺陷、阿尔茨海默病、痛经、嗜睡症、雷诺氏病、间歇性跛行、Sjogren综合征、偏头痛、心律失常、高血压、失神发作、肌肉萎缩症、口干症、2型糖尿病、高胰岛素血症、早产、秃发、癌症和免疫抑制等。
• SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS
  申请人：Christensen Mette Knak

  公开号：US20100227863A1

  公开（公告）日：2010-09-09

  The present application discloses substituted 3-(4-hydroxyphenyl)-indolin-2-one compounds (oxindole compounds) of the formula and the use of such compounds for the preparation of a medicament for the treatment of cancer in a mammal, in particular in humans.

  本申请公开了代替3-(4-羟基苯基)-吲哚-2-酮化合物（氧化吲哚化合物）的公式以及使用这种化合物制备哺乳动物，特别是人类的肿瘤药物的用途。